Related Experiment Video
Updated: Apr 18, 2026
Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
Published on: June 7, 2019
Genotyping of cutaneous melanoma
Isabella C Glitza1, Michael A Davies1
1Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, Texas 77030, USA.
Abstract:
Until recently, treatment options for patients with metastatic melanoma were very limited. This landscape has evolved dramatically since the discovery of activating mutations in the BRAF gene in ~45% of cutaneous melanomas. Vemurafenib, dabrafenib, and trametinib have all received regulatory approval for the treatment of metastatic melanoma patients with a BRAF mutation. Based on the necessity to document the presence of a BRAF mutation to prescribe these agents, molecular testing is now the standard of care in this disease. However, the options and rationale for testing are evolving rapidly due to an improved understanding of the molecular drivers and heterogeneity of melanoma. Such testing may identify rational combinatorial approaches to prevent or overcome resistance for the approved BRAF inhibitors. In addition, new clinical strategies have been identified for a number of other molecular changes that are detected in this disease, including somatic changes in NRAS, PTEN, CDKN2A, and c-KIT, among others. This review summarizes the current understanding of the genetic landscape of mutations in melanoma, their associations with clinicopathological features, and their implications for clinical testing and treatment.
Insights
Molecular testing for BRAF mutations is standard for metastatic melanoma treatment. Understanding melanoma
Area of Science:
- Oncology
- Genetics
- Dermatology
Background:
- Metastatic melanoma treatment was limited until BRAF mutations were discovered.
- Targeted therapies like vemurafenib, dabrafenib, and trametinib are approved for BRAF-mutated melanoma.
Purpose of the Study:
- To review the genetic landscape of melanoma mutations.
- To discuss the implications for clinical testing and treatment strategies.
Main Methods:
- Review of current understanding of melanoma genetics.
- Analysis of associations between mutations and clinicopathological features.
Main Results:
- Activating BRAF mutations occur in ~45% of cutaneous melanomas, guiding targeted therapy.
- Other key mutations include NRAS, PTEN, CDKN2A, and c-KIT.
- Molecular testing is crucial for treatment selection and resistance management.
Conclusions:
- The genetic landscape of melanoma is complex and evolving.
- Molecular testing is essential for personalized treatment and identifying novel therapeutic strategies.
- Further research into melanoma heterogeneity can guide combinatorial approaches and overcome resistance.
